Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Online Cancer Database Speeds Drug Discovery Process

By LabMedica International staff writers
Posted on 16 Dec 2010
A powerful new cancer drug-discovery database has been launched to speed up the process of bringing drugs from the research bench to point-of-care. More...


The Cancer Research UK-funded database--known as canSAR--has been set up by researchers at Cancer Research UK's Center for Cancer Therapeutics at The Institute of Cancer Research (ICR; London) to create a one-stop-shop for scientists worldwide. For the first time, it brings together all the relevant biological, chemical, pharmacological, and eventually clinical data about important genes and proteins in every type of cancer in a way that greatly aids the discovery of new drugs.

The freely available database allows scientists and clinicians to search through cancer-related data and information across the spectrum of research--from genomics to clinical trials--in a portion of the time it would earlier have taken them to collected this information.

Dr. Bissan Al-Lazikani, an ICR scientist who led the research team that developed canSAR, stated, "With the unprecedented amounts of electronic data being generated by modern molecular research techniques, the demand for a resource that brings together all this information and makes it available in a clear and manageable format is greater than ever. Previously the information was stored in many different locations and formats, which limited its effective use by researchers.”

Prof. Paul Workman, director of the Cancer Research UK Center for Cancer Therapeutics at the ICR, said, "We have already found canSAR to be fantastically useful in our own cancer drug discovery research. We are applying it to evaluate large number of potential drug targets in a faster and more systematic way than before and to select the best ones to work on. Having road tested it ourselves, I'm really excited about our powerful canSAR tool and I'm delighted to make it available to the cancer research community worldwide. Scientists can now, at the click of a button and at a single online location, rapidly identify the biological and structural characteristics of an actual or potential drug target, find the genes and proteins that it interacts with, assess its structural drugability and identify any small molecule chemical inhibitors. Researchers can also find information on the cancer cell lines that are most suitable for their experiments. This information is now available in minutes whereas it would previously have taken weeks to find.”

canSAR contains information on the entire human proteome--the protein equivalent of the human genome--as well as linking to data on more than 1,000 cancer cells lines, utilized by researchers to study the effect of new drugs in the lab. Significantly, scientists will also have improved access to information about all the chemical compounds known to be active on a particular drug target--tying the biology and chemistry together in a new way.

"For example, one can quickly look at data on 700,000 chemical compounds acting on 4,000 molecular targets. It contains a total of more than eight million experimental data points. Patients will benefit because researchers will be able to move more quickly from a basic research discovery to new drugs in the clinic,” added Prof. Workman.

Dr. Lesley Walker, Cancer Research UK's director of cancer information, said, "This new database will provide scientists with easy access to research being carried out by other specialist groups around the world, paving the way for a much more collaborative way of working. Hopefully, this will help accelerate the pace at which discoveries involving the nuts and bolts of cancer can be translated into effective new drugs in the clinic. I'd encourage all researchers to take advantage of this important resource.”

canSAR v1.0 can be accessed online (please see Related Links below), and is an integrated database and workbench that brings together biologic, chemical, pharmacologic (and ultimately clinical), data. Its goal is to integrate this information and make it accessible to cancer research scientists from multiple disciplines worldwide, in order to help with hypothesis generation in cancer research, and support drug discovery decisions.

Users can search canSAR using text queries, protein/gene name searches, any keyword searches, chemical structure searches, and sequence similarity searches. Moreover, users can explore and filter chemical compound sets, view experimental data, and produce summary plots.

Related Links:

Cancer Research UK
canSAR v1.0




Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
Homocysteine Quality Control
Liquichek Homocysteine Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.